Document Type
Article
Publication Date
2017
Keywords
serotonin syndrome, ifosfamide neurotoxicity, methylene blue
Digital Object Identifier (DOI)
https://doi.org/10.1177/1073274817729070
Abstract
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe encephalopathy complicating ifosfamide-based therapy for recurrent retroperitoneal leiomyosarcoma. After treatment with methylene blue, the patient experienced clinical decompensation and was diagnosed with serotonin syndrome based on a constellation of clinical findings. Withdrawal of methylene blue and other serotonergic medications led to clinical stabilization and ultimately neurological recovery. Our case highlights the challenge of diagnosing serotonin syndrome in the face of preexisting ifosfamide neurotoxicity, as there is significant clinical overlap between these 2 syndromes. Practitioners must remain vigilant of this potential life-threatening complication in this vulnerable population.
Rights Information
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Was this content written or created while at USF?
Yes
Citation / Publisher Attribution
Cancer Control, v. 24, issue 5, p. 1-4
Scholar Commons Citation
Snyder, Matthew; Gangadhara, Suhas; Brohl, Andrew S.; Ludlow, Steven; and Nanjappa, Sowmya, "Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue" (2017). Neurology Faculty Publications. 83.
https://digitalcommons.usf.edu/neur_facpub/83
